Rice Technologies for Cervical Cancer Screening and Diagnosis

Launched by M.D. ANDERSON CANCER CENTER · May 10, 2022

Keywords

ClinConnect Summary

The PEER Trial: Part 2 Rice Technologies is a study focused on improving the way we detect cervical cancer. Researchers want to see how well a new test called a lateral flow test works for finding HPV (a virus linked to cervical cancer) compared to other tests that are already available. They are also looking at a special imaging system that uses light to help identify changes in the cervix that could indicate cancer. This study is important because it aims to find more accurate and reliable methods for early detection of cervical issues.

To participate in this trial, women between the ages of 25 and 49 who have had an abnormal cervical cancer screening test may be eligible. Participants should have an intact cervix, be able to provide consent, and not be pregnant or breastfeeding. If you join the trial, you can expect to undergo various tests and procedures to help researchers gather important information about cervical health. If you're interested in participating or want more information, please speak with your healthcare provider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. 25 - 49 year old women
• • 2. Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test)
• • 3. Women with intact cervix
• • 4. Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding
• • 5. Willing and capable of providing informed consent
• Exclusion Criteria:
• • 1. Women under 25 or over 49 years old
• • 2. Women who have undergone a total hysterectomy (with removal of the cervix)
• • 3. Women who are pregnant or breastfeeding